39.98 0.00 (0.00%)
After hours: 4:52PM EDT
|Bid||40.00 x 1300|
|Ask||40.01 x 1800|
|Day's Range||39.55 - 40.13|
|52 Week Range||34.38 - 43.30|
|Beta (3Y Monthly)||0.45|
|PE Ratio (TTM)||42.08|
|Forward Dividend & Yield||1.40 (3.75%)|
|1y Target Est||45.10|
A major break through in the fight against lung cancer. Merck announced that its drug Keytruda has shown an increase in the survival for those suffering from lung cancer. Merck CFO Rob Davis talks with Yahoo Finance's Adam Shapiro and Julie Hyman.
AstraZeneca's (AZN) Tagrisso was approved by the FDA first for the treatment of epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer and then as a first-line therapy for EGFR-mutated NSCLC. The drug has become the highest-selling drug in AstraZeneca’s portfolio.
On its first-quarter earnings conference call, AstraZeneca (AZN) guided for year-over-year product sales growth in high-single-digit percentage in 2019. The company, however, expects modest product sales growth in the second half of 2019 due to higher oncology revenue in the previous period.
Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine
At Insider Monkey we follow nearly 750 of the best-performing investors and even though many of them lost money in the last couple of months of 2018 (some actually delivered very strong returns), the history teaches us that over the long-run they still manage to beat the market, which is why it can be profitable […]
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
In Phase IIIb DIALIZE trial, 41.2% of LOKELMA patients maintained normal potassium levels pre-dialysis compared to 1% receiving placebo
FARXIGA showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death in a pre-specified analysis from DECLARE-TIMI 58
A look at the shareholders of AstraZeneca PLC (LON:AZN) can tell us which group is most powerful. Institutions will...
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring.Source: Shutterstock Here's what you need to know about Sanofi's (NASDAQ:SNY) new CEO. * The new Sanofi CEO is Paul Hudson. * He will be taking over the role of CEO from Brandicourt starting on Sept. 1, 2019. * Hudson's most recent work includes serving as the CEO of Novartis Pharmaceuticals (NYSE:NVS) and being a member on the Novartis Executive Committee. * The new Sanofi CEO also has plenty of experience working with pharmaceutical companies over the last 28 years. * Some of his major previous employers include Schering Plough, Astra Zeneca (NYSE:AZN) and Novartis. * This has given him plenty of experience working in the markets of the U.S., Japan and Europe. * It has also awarded him the experience needed to handle leadership through his previous management roles. * Paul Hudson will also be moving to Paris, France to serve in his role as CEO of the company, which has its headquarter there. * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% Serge Weinberg, Chairman of the Board of Directors for Sanofi, has this to say about the change.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are very pleased that Paul Hudson has agreed to join Sanofi. His skills and experience give him all the assets he needs to accelerate growth and lead the Group's adaptation to new strategic challenges, particularly in the areas of Research and Development and digital. His human values will enable him to mobilize all the energies and increase the agility, that a group such as Sanofi needs, to face the new challenges of our industry and the changes in healthcare systems around the world."SNY stock was up 5% as of Friday morning. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% * 7 Stocks to Buy That Don't Care About Tariffs * 5 Healthcare Stocks to Pick Up From the Wreckage As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post New Sanofi CEO 2019: 8 Things to Know About Paul Hudson appeared first on InvestorPlace.
AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.
GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
British drugmaker AstraZeneca Plc is preparing to search for a successor to Chairman Leif Johansson, Sky News reported https://bit.ly/2Zals8B on Monday. AstraZeneca's board is in the early stages of planning for an eventual replacement for Johansson, who has chaired the company for seven years, according to the report. There was no scheduled timetable in place yet for Johansson's departure, Sky News reported, citing sources.
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.